Antibody–drug conjugates (ADCs) represent a novel and evolving class of antineoplastic
agents, constituted by monoclonal antibody linked to biologically active drugs, delivering …

Antibody-drug conjugates (ADCs) embody a simple, but elegant, vision for cancer therapy—
the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells …

Antibody–drug conjugates (ADCs) are a class of antineoplastic agents whose structure is
composed of three main components: a monoclonal antibody (mAB) targeting a specific …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer
address all aspects of management for breast cancer. The treatment landscape of metastatic …

Breast cancer, the most frequent female malignancy, is often curable when detected at an
early stage. The treatment of metastatic breast cancer is more challenging and may be …

Amplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in
15–20% of invasive breast cancers and is associated with an aggressive phenotype and …

PURPOSE Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)–
directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers …

Background The advent of targeted therapies signaled novel avenues for more optimal
oncological outcomes. Antibody-drug conjugates (ADCs) have risen as a cornerstone of the …

Case 17-2024: A 45-Year-Old Woman with Metastatic Breast Cancer | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Urothelial carcinoma (UC) is a prevalent malignant tumor involving the urinary system.
Although there are various treatment modalities, including surgery, chemotherapy, and …